Laurie Veltri, PA
Psychiatry · Toledo, OHNPI 1669976569
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,334 of the $20,455 with a category attached, or 84.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $6,813 and has fallen 61.3% since, to $2,638 in 2025. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,075 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$3K
- UCB, Inc.$2K
- Novartis$2K
- Jazz Pharmaceuticals Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Biogen$1K
- plus $10K from 54 others
What the payments were for
- Consulting fees$1,99510%
- Travel & lodging$4352%
- Food & beverage$17,33485%
- Education$6903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$2,430
- NOURIANZ$368
- VYVGART HYTRULO$225
- VALTOCO$113
How this compares
$20,455 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 29 | $214,289 |
| ZeposiaOzanimod Hydrochloride | 16 | $133,577 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $128,963 |
| IngrezzaValbenazine Tosylate | 13 | $122,390 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 36 | $118,220 |
| EpidiolexCannabidiol (Cbd) | 22 | $104,660 |
| BriviactBrivaracetam | 29 | $44,927 |
| Nurtec OdtRimegepant Sulfate | 20 | $36,124 |
| VraylarCariprazine Hcl | 22 | $30,392 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $22,070 |
| UbrelvyUbrogepant | 21 | $21,621 |
| KeppraLevetiracetam | 11 | $18,651 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $17,302 |
| QuliptaAtogepant | 12 | $16,466 |
| Rufinamide | 18 | $14,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $897 | $214,28929 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $23 | $133,57716 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,165 | $122,39013 claims |
| Grifols USA, LLCGamunex-C | $25 | $118,22036 claims |
| AbbVieVraylar, Ubrelvy, Qulipta | $1,097 | $68,47955 claims |
| UCB, Inc.Briviact | $2,237 | $44,92729 claims |
| PfizerNurtec Odt, Dilantin | $106 | $38,35334 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $71 | $17,30213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Toledo
- David JahnToledo$519K
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.